Correction: Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after

Abstract

Full text

**Correction to: Quality of Life Research (2023) 32:989–1003 ** 10.1007/s11136-022-03327-4

In the original publication of the article, the authors realized that the scores of two dimensions of the EORTC QLQ BR23 (Sexual Function and Sexual Enjoyment) were wrongly reversed while preparing the tables. This mistake affects two lines (Sexual Function and Sexual Enjoyment) of Table 4 and Supplementary Table (1.3.2, 1.3.3, 2.3.2 and 2.3.3). The correct version of Table 4 and the supplementary information are provided in this correction.Table 4. Mean scores and standard deviations of EORTC QLQ-BR-23 according to age, Charlson Comorbidity Index, and stageAllAgeComorbidity indexTumor stage < 4040–65 > 65p value0 ≥ 1p* value0IIIIIIp* valueAt diagnosisBody Image92.3 (16.7)87.5 (20.8)92.0 (17.0)94.5 (14.4)0.00392.4 (16.3)92.1 (18.4)0.77994.2 (12.6)92.6 (16.7)91.9 (17.2)89.8 (19.8)0.258Sexual Function23.5 (26.1)31.3 (27.1)27.4 (26.6)10.6 (19.2) < 0.00124.9 (25.8)18.2 (26.5) < 0.00124.7 (26.5)24.9 (26.1)21.1 (25.4)21.8 (28.3)0.126Sexual enjoy54.6 (29.1)59.4 (32.1)56.2 (28.8)42.5 (26.1) < 0.00155.3 (28.9)50.5 (29.9)0.14054.5 (26.6)54.8 (28.3)53.6 (29.7)57 (36.0)0.913Future perspective45.9 (31.9)36.4 (32.0)45.7 (31.7)48.8 (32.2)0.00945.8 (31.3)46.3 (34.2)0.82250.3 (29.9)45.8 (32.1)46.4 (32.4)39.2 (31.3)0.090Systemic therapy effects12.5 (13.9)11.5 (13.9)12.7 (14.4)12.4 (12.7)0.76412.2 (13.8)13.6 (14.3)0.16912.6 (13.5)11.8 (13.2)13.2 (14.8)14.4 (16.2)0.235Breast symptoms13.2 (16.9)19.2 (20.4)13.4 (16.9)11.1 (15.8)0.00113.7 (17.2)11.0 (15.6)0.02113.4 (17.2)12.5 (17.2)14.4 (16.7)12.9 (15.8)0.342Arm symptoms8.7 (15.6)6.4 (12.5)8.4 (14.7)10.0 (18.3)0.1278.2 (14.7)11.0 (18.5)0.0117.8 (14.0)8.4 (15.5)9.6 (15.8)8.6 (17.2)0.592Upset hair loss24.0 (31.6)12.3 (27.7)25.6 (33.2)23.6 (27.7)0.22323.5 (31.4)26.7 (33.1)0.56411.1 (18.5)22.9 (32.8)28.6 (32.5)33.3 (31.2)0.053At 2-year follow-upBody Image84.6 (24.6)79.7 (28.6)82.9 (25.8)88.8 (21.0)0.00184.6 (24.7)84.7 (24.4)0.95690.1 (18.3)86.7 (22.4)81.4 (27.0)73.5 (33.7) < 0.001Sexual Function20.9 (23.5)29.5 (21.0)25 (24.1)9.9 (17.9) < 0.00122.4 (24.0)15.4 (21.0) < 0.00123.8 (24.1)21.7 (24.3)18.9 (22.5)19 (19.8)0.163Sexual enjoy50.3 (27.8)62.8 (23.7)53.2 (27.0)34.3 (27.1) < 0.00151.3 (28.1)45.6 (26.2)0.07052.8 (26.3)51.3 (29.2)48.2 (27.1)47 (22.6)0.518Future perspective59.5 (32.1)55.9 (37.4)57.1 (31.9)65.0 (31.4)0.00159.2 (31.9)60.6 (33.0)0.55766.4 (29.3)59.6 (31.6)59.1 (32.4)48.4 (36.9)0.003Systemic therapy effects18.3 (16.5)12.2 (11.1)18.9 (16.8)17.9 (16.1)0.05617.7 (16.3)20.7 (17.3)0.01416.6 (15.4)17.8 (15.8)19.3 (17.8)21.1 (17.8)0.171Breast symptoms16.0 (17.8)17.4 (19.5)17.4 (18.0)13.0 (16.9)0.00115.8 (16.8)16.6 (21.0)0.57215.0 (18.5)16.0 (17.0)16.1 (18.7)17.2 (18.5)0.859Arm symptoms15.7 (20.3)9.5 (15.0)16.2 (20.3)15.5 (20.8)0.15715.0 (19.5)18.2 (23.0)0.03512.0 (18.0)14.2 (19.4)18.2 (21.0)22.8 (24.8) < 0.001Upset hair loss31.1 (33.7)13.9 (30.0)32.0 (33.4)31.2 (34.3)0.19229.4 (32.6)36.9 (36.7)0.05822.0 (26.8)29.8 (33.4)34.4 (34.5)42.0 (40.5)0.066EORTC QLQ-BR-23 differences according to age, comorbidity and stage were tested with ANOVA

The original article has been corrected.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 655 kb)